Prevention and treatment of human metabolic syndrome including type 2 diabetes, steatohepititis and related conditions using non-absorbable, orally administered compounds
Compounds and oral pharmaceutical compositions which neutralize microbially-produced electrophilic carbonyl species, comprising:a non-absorbable compound containing one or more nitrogen nucleophiles having a first pKa between 5 and 10, and a molecular weight less than 800,wherein said non-absorbable compound reacts locally in the gastrointestinal tract and combines with microbially-produced electrophilic carbonyl species by C—；N bond formation, thereby protecting gastrointestinal peptide hormones containing arginine or lysine residues, and also preventing diffusion of said electrophilic species into systemic circulation where they may cause damage to proteins, DNA or RNA that adversely affects health； and a pharmaceutically acceptable carrier or excipient.
